Abstract
Stimulation of human platelets with the thromboxane A2 analogue, U46619, after treatment with prostaglandin E1 or forskolin, reduced the inhibition of ADP-evoked Mn2+ influx and the release of Ca2+ from intracellular stores. U46619 decreased the elevated concentration of 3',5'-cyclic AMP in platelets that were pretreated with prostaglandin E1. These results suggest that occupation of prostaglandin H2/thromboxane A2 receptors, like those for other agonists, inhibits adenylate cyclase activity, which can contribute to the promotion of platelet activation.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenosine Diphosphate / antagonists & inhibitors
-
Adenosine Diphosphate / physiology
-
Adenylyl Cyclase Inhibitors*
-
Alprostadil / antagonists & inhibitors*
-
Calcium / metabolism
-
Colforsin / pharmacology
-
Cyclic AMP / metabolism*
-
Fura-2
-
Humans
-
Manganese / metabolism
-
Platelet Activation*
-
Prostaglandin Endoperoxides, Synthetic / pharmacology*
-
Receptors, Prostaglandin / metabolism*
-
Receptors, Thromboxane
-
Thromboxane A2 / metabolism*
Substances
-
Adenylyl Cyclase Inhibitors
-
Prostaglandin Endoperoxides, Synthetic
-
Receptors, Prostaglandin
-
Receptors, Thromboxane
-
Colforsin
-
Manganese
-
Thromboxane A2
-
Adenosine Diphosphate
-
Cyclic AMP
-
Alprostadil
-
Calcium
-
Fura-2